Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4281 trials
Conditions Breast Cancer Metastatic, Breast Cancer ...
Phase PHASE1, PHASE2
Enrollment 74
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

In phase Ib, our study is aimed to evaluate the safety and tolerance of SHR-A1811 combined with pyrotinib in breast cancer with brain metastasis, and confirm the recommended phase 2 dose combined with preliminary results of efficacy. In phase II, our study is aimed to evaluate the efficacy and safety of SHR-A1811 combined with pyrotinib and bevacizumab at RP2D in breast cancer with brain metastasis.

Design

Study type: Interventional Phases: Phase1, Phase2 Allocation: Non Randomized Intervention model: Sequential Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: SHR-A1811 — ADC
  • Drug: Bevacizumab — bevacizumab biosimilar
  • Drug: Pyrotinib — anti-HER2 inhibitor

Primary Outcomes

  • RP2D in phase Ib (From the enrolment of the first subject, to the end of Cycle 6 completion or disease progression or dose discontinuation due to AE in the last enrolled subject)
  • CNS-ORR by investigator in phase II (At baseline, at the time point of every 6 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1, PHASE2
Status: Recruiting
Start Date: 2025-01-08
Completion: 2027-02-28
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 74 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Fudan University
Principal Investigators:
  • Hongxia Wang, Chief physician (PRINCIPAL_INVESTIGATOR) - Fudan University
  • Biyun Wang, Chief physician (PRINCIPAL_INVESTIGATOR) - Fudan University
Contact Information
Study Contact:
Hongxia Wang, Chief physician
+8621-38196379
whx365@126.com
Ting Li, Associate chief physician
+86-18121299346
cinderellaliting@126.com
Hongxia Wang, Chief physician
+8621-38196379
whx365@126.com
Fudan Cancer Hospital
Interventions
  • Drug: SHR-A1811 — ADC
  • Drug: Bevacizumab — bevacizumab biosimilar
  • Drug: Pyrotinib — anti-HER2 inhibitor
Study Locations (1 sites)
Fudan Cancer Hospital, Shanghai, Shanghai Municipality 200230 China
Eligibility Criteria
Inclusion Criteria: * More than 18 years old; * ECOG PS Score: 0\~2; * Patients must have a life expectancy ≥ 3 months; * Brian metastasis confirmed by MRI, at least one measurable brain lesion based on RANO-BM with no prior radiotherapy; * Mannitol or hormone therapy is allowed to use for brain metastasis before enrolment, but treatment dosage should be stable for one week and not need to be increased; * Adequate organ function and marrow function; * Has recovered from any AEs (≤ grade 1) related to prior anti-tumour treatments before first dose of study therapy, except: a. alopecia; b. hyperpigmentation; * Willing to join in this study, able to provide written informed consent, good compliance and willing to cooperate with follow-up. Exclusion Criteria: * Has leptomeningeal metastasis or cystic metastatic lesions confirmed by MRI or lumbar puncture; * Existence of third space fluid (e.g. massive ascites, pleural effusion, pericardial effusion) that is not well controlled by effective methods, e.g. drainage; * Has CNS complications with the need for emergency intervention, or brain metastasis with poorly controlled symptoms by hormone or dehydration therapy, such as uncontrollable intracranial hypertension, mental disorder or epilepsy; * Prior bevacizumab or EGFR-TKI is allowed, but should meet the following requirements at the same time: 1. No disease progression during prior bevacizumab or EGFR-TKI; 2. More than 3 months from the interruption of bevacizumab or EGFR-TKI to disease progression; * Has received whole brain radiotherapy, chemotherapy, surgery within 2 weeks before first dose of study therapy; has received trastuzumab-based therapy or endocrine therapy within one week before first dose of study therapy; has received palliative radiotherapy for bone metastasis within 2 weeks before first dose of study therapy; * Has known clinically significant lung disease, that is, moderate-to-severe lung disease which severely affects respiratory function, including but not limited to: idiopathic pulmonary fibrosis, pneumonitis. Prior ≥ grade 3 interstitial lung disease is not allowed to enrolment; * Has received full-dose anticoagulants or thrombolytics within 10 days before enrolment, or non-steroid anti-inflammatory drugs with platelet inhibition (except low-dose aspirin (≤325mg qd) for preventive use); * Existence of unhealed wound, active gastric ulcer, and other diseases which may cause haemorrhage risk (e.g., prior major operation within 4 weeks before enrolment, prior arterial or venous thrombotic event within one year before enrolment, prior cerebralvascular accident); * Has known hereditary haemorrhagic tendency or coagulation disorder; * Has joined in other clinical drug trials within 2 weeks before enrolment; * Use of other antitumor systemic treatment during the study at the same time, except bisphosphonates for the treatment of bone metastasis or osteoporosis prevention; * Other malignancy within prior 5 years unless curatively treated with no evidence of disease for at least recent 3 years, except: curatively treated in situ cancer of the cervix, skin basal cell carcinoma or skin squamous cell carcinoma; * Cardiac insufficiency, including but not limited to: congestive heart failure, transmural myocardial infarction, angina which needs drug treatments, clinically significant valvulopathy and high-risk arrhythmia, or QTc abnormity with clinical significance in ECG examination during the screening period (corrected QTc \>450 msec \[male\] or QTc \>470 msec \[female\] under the resting state); * Uncontrolled hypertension (under the resting state: systolic pressure \>160mmHg or diastolic pressure \>100mmHg); * Other diseases which may affect study results, including but not limited to: 1) known history of immunodeficiency, including HIV-positive, other acquired or innate immunodeficient disease, or known history of organ transplantation; 2) HBsAg-positive and HBV DNA≥1000 IU/mL, or HCV antibody-positive, or treponema pallidum antibody-positive; 3) hypersensitivity to study therapy or any of its excipients; 4) severe infection requiring antibiotics, antiviral or antifungal treatment; * Female patients during the gestation or suckling period, of childbearing potential and pregnancy test-positive, or unwilling to use an effective method of contraception during the whole study; * Inability to swallow, intestinal obstruction or existence of other factors affecting medication and absorption; * Any other conditions not appropriate for study enrolment in the opinion of the investigator.
Conditions Preeclampsia (PE)
Phase Not Applicable
Enrollment 400
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this observational study is to learn about the effects of the different drug regimens of magnesium sulphate in treatment of (severe pre-eclampsia). This condition affects some pregnant women and raises their blood pressure. It may also cause seizures (fits). The medication (magnesium sulphate) helps to prevent seizures. The main question this study aims to answer is: What are the different regimens of magnesium sulphate that are used to prevent seizures in pregnant women with severe pre-eclampsia? Participants already have taken the magnesium sulphate as part of their regular medical care for severe pre-eclampsia. Researchers will look into the records of the participants in the past 5 years to collect the data.

Design

Study type: Observational Observational model: Cohort Time perspective: Retrospective

Primary Outcomes

  • Occurrence of eclamptic fits (within 24 hours before or after delivery)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2024-12-03
Completion: 2026-03
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 400 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Ain Shams Maternity Hospital
Contact Information
Study Contact:
Rania HM Ahmed, MD
20201200522444
raneyah@med.asu.edu.eg
Sherif Ashoush, MD
sherifashoush@med.asu.edu.eg
Sherif Ashoush, MD
20201222660266
sherifashoush@med.asu.edu.eg
Ain Shams University Maternity Hospital
Interventions
N/A
Study Locations (1 sites)
Ain Shams University Maternity Hospital, Cairo, Egypt
Eligibility Criteria
Inclusion Criteria: * All hospital records of patients diagnosed as preeclampsia with severe features planned to receive magnesium sulphate. Exclusion Criteria: * Records with missing data about the regimen of magnesium sulphate used
Conditions Sleep Problems, Depressive Disorder and ...
Phase NA
Enrollment 60
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The purpose of this study is to examine the effect that melatonin lotion has on sleep quality, the nervous system, and mental health. Melatonin is a hormone secreted by the brain that regulates sleep and might improve depression and anxiety symptoms. The goal is to determine whether melatonin in lotion form is an effective treatment for young adults with inadequate sleep and might improve mental health. Participants will fill out surveys, wear an actigraph (a wrist-worn device that measures sleep), wear a heart rate monitor (a strap worn around one's chest), and provide nightly saliva samples during treatment weeks. In one of the two treatment weeks, participants will receive a lotion that contains melatonin. During the other week they will receive a control treatment that will be lotion with no melatonin, and there will be a week in between with no treatment at all.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Crossover Primary purpose: Basic Science Masking/blinding: Triple

Interventions / Regimen

  • Other: Melatonin lotion — 3 g lotion applied one hour before bedtime
  • Other: Placebo lotion — 3 g of placebo lotion (scent-matched control) applied one hour before bedtime

Primary Outcomes

  • Sleep disturbance (Measured pre-treatment, at end of placebo week, and at end of active treatment week (3 weeks total))
  • Anxiety (Measured pre-treatment, at end of placebo week, and at end of active treatment week (3 weeks total))
  • Depression (Measured pre-treatment, at end of placebo week, and at end of active treatment week (3 weeks total))
  • Total sleep time (Two weeks of data separated by a one week period)
  • Sleep efficiency (Two weeks of data separated by a one week period)
  • Normalized high frequency power of heart rate variability (Two weeks of data separated by a one week period)
  • Anxiety by momentary ecological assessment (Three times per day for two weeks of data separated by a one week period)
  • Mood by momentary ecological assessment (Three times per day for two weeks of data separated by a one week period)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-02-28
Completion: 2028-04-01
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 60 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Redlands
Principal Investigators:
  • Lisa E Olson, Ph.D. (PRINCIPAL_INVESTIGATOR) - University of Redlands
Contact Information
Study Contact:
Lisa E Olson, Ph.D.
909-748-8524
lisa_olson@redlands.edu
Steven Moore, Ph.D.
(909) 748-8687
steven_moore@redlands.edu
Lisa Olson, Ph.D.
909-748-8524
lisa_olson@redlands.edu
University of Redlands
Interventions
  • Other: Melatonin lotion — 3 g lotion applied one hour before bedtime
  • Other: Placebo lotion — 3 g of placebo lotion (scent-matched control) applied one hour before bedtime
Study Locations (1 sites)
University of Redlands, Redlands, California 92374 United States
Eligibility Criteria
Inclusion Criteria: * a T score ≥ 48 on the sleep disturbance short form Patient-Reported Outcomes Measurement Information System (PROMIS) measure, and * a T score ≥ 55 on the anxiety or depression short form PROMIS measures (mild symptoms or more) Exclusion Criteria: * currently using antidepressant, anti-anxiety, or sleep medication including melatonin * are pregnant * have allergies/sensitivities to scented lotion * are unwilling to commit to keeping a similar bedtime (± 1 hour) during treatment weeks.
Conditions Breast Cancer Survivor
Phase PHASE2
Enrollment 200
Locations 9 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The researchers are doing this study to compare two different types of group therapy and find out whether they are effective approaches for helping breast cancer survivors manage joint pain caused by aromatase inhibitors (AI). This type of joint pain is called AI-associated arthralgia, or AIA, and it is common in people taking AIs. AIA and its associated symptoms can make some people decide to stop taking their medication. The study will look at the effects of two different types of group therapy on participants' cancer-related symptoms (such as pain, fatigue, and anxiety), their ability to continue taking AIs on a regular schedule, and their quality of life. We will measure participants' quality of life by having them fill out questionnaires. Both groups will have 2-hour group therapy sessions once a week, over the course of 8 weeks. During the sessions, you will be in a group of 6-10 participants, who may be a mixture of patients from both MSK and University of California San Diego (UCSD).

Design

Study type: Interventional Phases: Phase2 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Double

Interventions / Regimen

  • Behavioral: Mindfulness Oriented Recovery Enhancement (MORE) — eight weekly two-hour MORE sessions
  • Other: Questionnaires — filled out up to 24 weeks
  • Behavioral: Supportive Psychotherapy (SG) — eight weekly two-hour SG sessions

Primary Outcomes

  • Pain Interference (up to 24 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2024-12-06
Completion: 2028-12
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 200 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Memorial Sloan Kettering Cancer Center
Collaborators: National Institutes of Health (NIH)
Principal Investigators:
  • Jun Mao, MD, MSCE (PRINCIPAL_INVESTIGATOR) - Memorial Sloan Kettering Cancer Center
Contact Information
Study Contact:
Jun Mao, MD, MSCE
646-608-8553
maoj@mskcc.org
Karolina Bryl, PhD
646-608-8573
brylk@mskcc.org
Eric Garland, PhD, LCSW
801-581-3826
University of California San Diego (Data collection and Data analysis)
Interventions
  • Behavioral: Mindfulness Oriented Recovery Enhancement (MORE) — eight weekly two-hour MORE sessions
  • Other: Questionnaires — filled out up to 24 weeks
  • Behavioral: Supportive Psychotherapy (SG) — eight weekly two-hour SG sessions
Study Locations (9 sites)
University of California San Diego (Data collection and Data analysis), San Diego, California 92103 United States
Florida State University, Tallahassee, Florida 32306 United States
Memorial Sloan Kettering Basking Ridge (All Protocol Activities), Basking Ridge, New Jersey 07920 United States
Memorial Sloan Kettering Monmouth (All Protocol Activities), Middletown, New Jersey 07748 United States
Memorial Sloan Kettering Bergen (All Protocol Activities), Montvale, New Jersey 07645 United States
Memorial Sloan Kettering Suffolk- Commack (All Protocol Activities), Commack, New York 11725 United States
Memorial Sloan Kettering Westchester (All Protocol Activities), Harrison, New York 10604 United States
Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York, New York 10065 United States
Memorial Sloan Kettering Nassau (All Protocol Activities), Uniondale, New York 11553 United States
Eligibility Criteria
Inclusion Criteria: * Age ≥18 years * English-proficient women with a history of stage I, II, or III breast cancer * Free of oncologic disease by clinical examination and history; * Receiving third-generation AI therapy (anastrozole, letrozole, or exemestane) for at least 28 days prior to consent with plan to continue for at least another 12 months; * Worst joint pain rated at least 4 or greater on a 0-10 numeric rating scale in the preceding week prior to consent; * Reporting at least 15 days with pain in the preceding 30 days prior to consent; * Experiencing joint pain for at least one month; * Pain attributed to AI therapy; * Willing to adhere to all study-related procedures, including randomization to one of two treatment arms: Mindfulness-Oriented Recovery Enhancement (MORE) or Supportive Group Psychotherapy (SG); * Able to attend video-call sessions in a quiet/private location. Exclusion Criteria: * Metastatic breast cancer (stage IV); * Completed chemotherapy, surgery, or radiation therapy less than 4 weeks prior to enrollment; * Pain attributed to inflammatory arthritis (i.e. rheumatoid arthritis, gout, pseudogout); * Surgery or joint injection involving the affected joints within the last month or planned within the next six months; * Active suicidality or psychosis as determined by the Mini-International Neuropsychiatric Interview.
Conditions Breast Cancer, Node-positive Breast Canc...
Phase PHASE2
Enrollment 120
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The purpose of the study is to determine the frequency of systemic metastasis in node positive breast cancer following chemotherapy and surgery. Participants will be asked to spend about 6 months in this study. Participants will undergo a computed tomography (CT) screening of the thorax, abdomen, and pelvis at baseline prior to adjuvant radiation therapy and another CT screening of the thorax, abdomen, and pelvis at 6 months if the baseline CT is found to be negative.

Design

Study type: Interventional Phases: Phase2 Allocation: Non Randomized Intervention model: Parallel Primary purpose: Screening Masking/blinding: None

Interventions / Regimen

  • Other: CT Scan — Participants will undergo a screening CT thorax, abdomen, pelvis at baseline prior to adjuvant radiation therapy and additional screening CT thorax, abdomen, and pelvis at 6 months if the baseline CT is found to be negative.

Primary Outcomes

  • Systemic Metastasis (Baseline and 6 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2025-02-24
Completion: 2026-10
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 120 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute
Collaborators: Florida Breast Cancer Foundation
Principal Investigators:
  • Kamran Ahmed (PRINCIPAL_INVESTIGATOR) - Moffitt Cancer Center
  • Matthew Mills (PRINCIPAL_INVESTIGATOR) - Moffitt Cancer Center
Contact Information
Study Contact:
Marian Hernandez
813-745-1807
marian.hernandez@moffitt.org
Kamran Ahmed, MD
Moffitt Cancer Center
Matthew Mills, MD
Moffitt Cancer Center
Interventions
  • Other: CT Scan — Participants will undergo a screening CT thorax, abdomen, pelvis at baseline prior to adjuvant radiation therapy and additional screening CT thorax, abdomen, and pelvis at 6 months if the baseline CT is found to be negative.
Study Locations (1 sites)
Moffitt Cancer Center, Tampa, Florida 33612 United States
Eligibility Criteria
Inclusion Criteria: * Histologic diagnosis of breast cancer with documentation of ER/PR/HER2 status. * HR+ will be defined as ER and/or PR ≥ 10%. To be classified as HER2+ disease, overexpression of HER2 by either IHC or in-situ hybridization is necessary as defined by the ASCO / CAP Guidelines27. Triple negative will be classified as ER and PR \<10% and HER2-. * Node positive HER2+ and triple negative breast cancer (ypN+) following receipt of neoadjuvant chemotherapy. HR+/HER2- patients should have ypN2 or ypN3 disease following receipt of neoadjuvant chemotherapy and surgery. * Patient must have completed a minimum of 8 weeks of standard neoadjuvant chemotherapy consisting of an anthracycline and/or taxane-based regimen. To include HER2 directed therapy for HER2+ patients. * Age ≥ 18. * Life expectancy ≥ 6 months. * Eastern Cooperative Oncology Group performance status 0 to 2. * Patients must be able to understand and the willingness to sign an informed consent for study procedures. * Ability to understand and stated willingness to comply with all study procedures and availability for the duration of the study. Exclusion Criteria: * Prior diagnosis of systemic metastases. * Patients with prior history of non-breast cancer malignancies should have NED ≥ 2 years excluding adequately treated non-melanoma skin cancer, in situ cancer of the cervix or bladder. * Contraindication towards CT IV contrast. * Chronic kidney disease stage IV or V or end stage renal disease (CrCl \<30 ml/min).
Conditions Breast Cancer
Phase NA
Enrollment 248
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Women with breast cancer make up a significant proportion of cancer survivors, with more than 43,750 women living with breast cancer in Ireland. However, many women report physical and psychological health difficulties that interfere with their ability to return to work. In Ireland, and internationally, these difficulties are being increasingly recognised, with recent research identifying gaps in rehabilitation services to prepare women with breast cancer to return to work. Collaborating with women with breast cancer, and those who provide health and supportive services to individuals living with cancer in Ireland, an online self-management intervention, CanWork, was developed. CanWork aims to support women with breast cancer to manage the process of returning to work and learn strategies to manage post-treatment health-related difficulties. CanWork also provides information on workplace entitlements. This intervention was trialled with women with breast cancer in 2021, who reported that the programme gave them confidence to return to work and that the content was relevant. This study will include a larger group of women with breast cancer to determine if CanWork is effective in supporting return to work. To do this, 248 women with breast cancer will be included in the study, half of whom will receive CanWork and the results will be compared with women who do not receive the intervention. Having a programme that is financially viable is important and therefore the costs involved in running and attending the intervention will also be calculated. Should this study demonstrate that CanWork is effective in supporting women with breast cancer to return to work, the study team will collaborate with cancer services in Ireland to make the programme available nationally.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Supportive Care Masking/blinding: Single

Interventions / Regimen

  • Other: CanWork — CanWork is an online, occupational therapy intervention to develop knowledge and skills to manage cancer-related symptoms that interfere with return to work. It consists of five, 90-minute group-based modules and an individual meeting between the occupational therapist facilitator and each participant. Each of the five-week group-based modules consists of two components: (i) education and peer-led discussion of cancer-related symptom management and supports available to manage difficulties in work and (ii) goal setting to facilitate application of knowledge and skills to work-related activities. Weekly topics include managing fatigue in work, understanding cancer-related cognitive impairments, strategies for managing physical and mental health in work and effective communication with employers and colleagues. The individual meeting between each participant and the occupational therapist is focused on designing a tailored return to work plan for each participant.

Primary Outcomes

  • Return to work: Yes/No. (From enrolment to 12-months following enrolment)
  • Return to Work Self-efficacy (RTW-SE) questionnaire (From enrolment to 12-months following enrolment)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-11-13
Completion: 2028-03-31
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 248 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Dublin, Trinity College
Collaborators: National Cancer Control Programme, Ireland, Royal College of Surgeons, Ireland, University of Galway
Principal Investigators:
  • Deirdre Connolly, PhD (PRINCIPAL_INVESTIGATOR) - University of Dublin, Trinity College
Contact Information
Study Contact:
Deirdre Connolly, PhD
018963216
connoldm@tcd.ie
Nickola Pallin, PhD
018963216
palinn@tcd.ie
Helen Greally, PhD
+353 91 540040
support@cancercarewest.ie
Cancer Care West
Interventions
  • Other: CanWork — CanWork is an online, occupational therapy intervention to develop knowledge and skills to manage cancer-related symptoms that interfere with return to work. It consists of five, 90-minute group-based modules and an individual meeting between the occupational therapist facilitator and each participant. Each of the five-week group-based modules consists of two components: (i) education and peer-led discussion of cancer-related symptom management and supports available to manage difficulties in work and (ii) goal setting to facilitate application of knowledge and skills to work-related activities. Weekly topics include managing fatigue in work, understanding cancer-related cognitive impairments, strategies for managing physical and mental health in work and effective communication with employers and colleagues. The individual meeting between each participant and the occupational therapist is focused on designing a tailored return to work plan for each participant.
Study Locations (2 sites)
Cancer Care West, Galway, Ireland
Solas Cancer Support Centre, Waterford, Ireland
Eligibility Criteria
Inclusion Criteria: * Women with confirmed diagnosis of breast cancer * Women with breast cancer who were in paid employment prior to their cancer diagnosis * Women with breast cancer who have completed adjuvant oncology treatment (excluding hormone therapy, targeted and biological therapies) within the last 12 months * Women with breast cancer who have capacity to participate in a six-week online occupational therapy intervention Exclusion Criteria: * Women with metastatic breast cancer * Women with breast cancer who were not in paid employment prior to their cancer diagnosis * Women with breast cancer who have decided not to return to work following completion of cancer treatment * Women with breast cancer who have co-morbidity that would interfere with capacity to participate in a six-week online occupational therapy intervention
Conditions Glaucoma
Phase NA
Enrollment 46
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Glaucoma is an irreversible optic neuropathy. It is the second most common cause of blindness worldwide. Glaucoma can be treated with topical medications (eye drops), laser or surgery. Traditional surgery is invasive and has a high complication rate (hypotonia, endophthalmitis, cataracts, etc.). As a result, several types of micro-invasive surgery (MIGS) have been developed to reduce the risks of surgery while maintaining their effectiveness in lowering intraocular pressure (IOP). The ELIOS laser system is the only ophthalmological excimer laser designed for the surgical treatment of glaucoma. The aim of the procedure is to ablate the trabecular meshwork and inner wall of Schlemm´s canal ab interno, with the creation of 10 microchannels of 210 um in the trabeculum using the ELIOS laser with a wavelength of 308 nm, in order to improve trabecular outflow to achieve a reduction in IOP. The ELIOS laser is an example of Microinvasive Glaucoma surgery (MIGS) with published results demonstrating efficacy and safety. The ELIOS laser is already in use in France (AMM / CE mark achieved). Its use as part of a prospective interventional study will enable us to collect data in order to treat patients more effectively and improve the quality of care provided to glaucoma patients.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Device: Surgery with ELIOS laser — This surgery involves visualizing the iridocorneal angle before or after cataract surgery, inserting the ELIOS laser probe into the anterior chamber to come into slight contact with the trabecular meshwork, then pressing the foot pedal, the surgeon activates the laser, which creates a microchannel by photoablating the trabecular meshwork and inner wall of Schlemm´s canal (trabeculostomy) ± 210 um in diameter. This gesture is repeated until 10 microchannels are created. The creation of these microchannels enhances the natural outflow of aqueous humor by bypassing the site of major resistance in the system. The usual duration of the ELIOS procedure is typically few minutes). The rest of the surgery does not deviate from standard phacoemulsification.

Primary Outcomes

  • Intraocular pressure (IOP) (day 0, 7 and 30, and month 3, 6 and 12 months after surgery)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-01-05
Completion: 2028-02-28
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 46 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Hôpital Privé de la Baie
Contact Information
Study Contact:
Ana Miguel, MD
+33787016187
myworld_ana@hotmail.com
Ana Miguel, MD
+332 33 50 90 90
Hôpital Privé de la Baie
Interventions
  • Device: Surgery with ELIOS laser — This surgery involves visualizing the iridocorneal angle before or after cataract surgery, inserting the ELIOS laser probe into the anterior chamber to come into slight contact with the trabecular meshwork, then pressing the foot pedal, the surgeon activates the laser, which creates a microchannel by photoablating the trabecular meshwork and inner wall of Schlemm´s canal (trabeculostomy) ± 210 um in diameter. This gesture is repeated until 10 microchannels are created. The creation of these microchannels enhances the natural outflow of aqueous humor by bypassing the site of major resistance in the system. The usual duration of the ELIOS procedure is typically few minutes). The rest of the surgery does not deviate from standard phacoemulsification.
Study Locations (1 sites)
Hôpital Privé de la Baie, Avranches, 50300 France
Eligibility Criteria
Inclusion Criteria: * Patients ≥ 18 years of age who agree to take part in the study and have signed an informed consent form * Visually significant cataract with indication for surgery * Primary open-angle glaucoma, or secondary open-angle glaucoma (pseudoexfoliative glaucoma or pigmentary glaucoma) with indication for cataract surgery. * Open iridocorneal angle (Shaffer classification grade 2-4) * Early to moderate glaucoma (advanced glaucoma, with MD from VFs worse than -12dB, will be excluded) Exclusion Criteria: * Presence of severe systemic pathologies 2024-A01891-46\_Protocol\_V6\_21112024\_Elios Page 20 / 58 * Pregnant or breastfeeding women * \<18 years of age * Presence of other ophthalmological pathologies (except cataracts), and exclusion of severe dry eye. * History of intraocular surgery, trauma, or conjunctival scarring in the quadrant intended for surgery * Visual acuity worse than "counting fingers". * Closure of the iridocorneal angle (and angle-closure glaucoma), angle-closure glaucoma secondary to iridocorneal synechiae, neovascular glaucoma or neovascularization of the iris. * Normal-pressure glaucoma * Pachymetry \< 490 um or \> 620 μm * Glaucomatous visual field with mean deviation worse than ≤-12 dB * IOP \> 35 mmHg * Autoimmune disorder, especially collagenosis * Patient under protective supervision * Patient not covered by a social security scheme
Conditions Healthy Volunteers Essential Hypertensio...
Phase PHASE1
Enrollment 160
Locations 3 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Part 1 : To evaluate the safety of single-dose KK3910 in healthy volunteers. Part 2 : To evaluate the safety of multiple-dose KK3910 in patients with essential hypertension. Part 3 : To assess the safety profile of repeated dosing of KK3910 in an additional hypertension cohort.

Design

Study type: Interventional Phases: Phase1 Allocation: Randomized Intervention model: Sequential Primary purpose: Treatment Masking/blinding: Triple

Interventions / Regimen

  • Drug: Placebo — Placebo is administered single dose or multiple dose by SC injection.
  • Drug: KK3910 — KK3910 is administered single dose or multiple dose by SC injection.

Primary Outcomes

  • Number of participants with adverse events (AEs) (Part 1 : Day 1 to Day 85, Part 2: Day 1 to Day 155, Part 3: Day 1 to Day 155)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1
Status: Recruiting
Start Date: 2025-04-03
Completion: 2027-12
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: true
Enrollment: 160 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Kyowa Kirin Co., Ltd.
Principal Investigators:
  • Tatsuhiko Makine (STUDY_CHAIR) - Kyowa Kirin Co., Ltd.
Contact Information
Study Contact:
Kyowa Kirin Co., Ltd.
+81-3-5205-7200
clinical.info.jp@kyowakirin.com
Kyowa Kirin Co., Ltd.
+81-3-5205-7200
clinical.info.jp@kyowakirin.com
SOUSEIKAI PS Clinic
Kyowa Kirin Co., Ltd.
+81-3-5205-7200
clinical.info.jp@kyowakirin.com
Medical Corporation Heishinkai OPHAC Hospital
Interventions
  • Drug: Placebo — Placebo is administered single dose or multiple dose by SC injection.
  • Drug: KK3910 — KK3910 is administered single dose or multiple dose by SC injection.
Study Locations (3 sites)
SOUSEIKAI PS Clinic, Hakata, Fukuoka 812-0025 Japan
Medical Corporation Heishinkai OPHAC Hospital, Yodogawa, Osaka 532-0003 Japan
Kitasato University Kitasato Institute Hospital, Minato-ku, Tokyo 108-8642 Japan
Eligibility Criteria
Inclusion Criteria: Part 1 * Voluntary consent to participate in this study must be given (in writing) * Japanese healthy adults or non-Asian healthy men 18 to \< 55 years at the time of informed consent ( Japanese healthy adults 65 to \< 80 years for the elderly cohort) * BMI is within the specified range at screening Inclusion Criteria: Part 2 * Voluntary consent to participate in this study must be given (in writing) * Japanese patients with essential hypertension, aged 18 to \<65 years at the time of informed consent * BMI is within the specified range at screening Inclusion Criteria: Part 3 * Voluntary consent to participate in this study must be given (in writing) * Japanese patients with essential hypertension, aged 18 to \<80 years at the time of informed consent * BMI is within the specified range at screening Exclusion Criteria: Part 1 * History of any respiratory disease, heart disease, gastrointestinal disease, renal disease, liver disease, psychiatric disorder, autoimmune disease, or malignant tumor that may affect assessments in the study, as judged by principal investigator or subinvestigator. * History of or current drug allergy * History of or current alcoholism or drug addiction * Smoking within the specified period * infection within the specified period * Any condition judged by the investigator or subinvestigator to be unsuitable for participation in the study Exclusion Criteria: Part 2 * History of any respiratory disease, heart disease, gastrointestinal disease, renal disease, liver disease, psychiatric disorder, autoimmune disease, or malignant tumor that may affect assessments in the study, as judged by principal investigator or subinvestigator. * History or of current drug allergy * History of or current alcoholism or drug addiction * Pregnant or breastfeeding patients, or patients willing to have a child during the study * Smoking within the specified period * infection within the specified period * Any condition judged by the investigator or subinvestigator to be unsuitable for participation in the study Exclusion Criteria: Part 3 * History of any respiratory disease, heart disease, gastrointestinal disease, renal disease, liver disease, psychiatric disorder, autoimmune disease, or malignant tumor that may affect assessments in the study, as judged by principal investigator or subinvestigator. * History or of current drug allergy * History of or current alcoholism or drug addiction * Pregnant or breastfeeding patients, or patients willing to have a child during the study * Smoking within the specified period * infection within the specified period * Any condition judged by the investigator or subinvestigator to be unsuitable for participation in the study
Conditions Depression, Parent-Child Relations
Phase NA
Enrollment 180
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this mechanistic clinical trial is to examine whether parent-coaching aimed at increasing child positive affect will increase child neural response to reward. The main questions it aims to answer are: Aim 1. Characterize child neural reward response and its relation to maternal socialization of positive emotions at baseline in healthy young children. Aim 2. Evaluate how coaching-related changes in maternal socialization of positive emotion expression contribute to increases in child neural reward response over time. Aim 3. Examine how maternal socialization of positive emotion expression contributes to increases in child neural reward response in the moment. Participating mother-child dyads will be randomized to either 3 sessions of parent coaching of child positive affect or 3 sessions of a general parenting support intervention and neural response to reward and affective behavior will be examined pre and post intervention.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Basic Science Masking/blinding: Double

Interventions / Regimen

  • Behavioral: Parent Coaching — Three sessions of parent coaching of child positive affect will be administered based on modules from PCIT-ED.
  • Behavioral: Active Control — General parent support and psychoeducation based on components of standard PCIT.

Primary Outcomes

  • Reward Positivity (RewP) (From baseline week 1 to final assessment week 5 (week 10 maximum))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-10-28
Completion: 2029-02-01
Eligibility
Age: 4 Years and older
Sex: ALL
Volunteers: true
Enrollment: 180 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Pittsburgh
Collaborators: National Institute of Mental Health (NIMH)
Principal Investigators:
  • Judith M Morgan, PhD (PRINCIPAL_INVESTIGATOR) - University of Pittsburgh
  • Lauren M. Bylsma, PhD (PRINCIPAL_INVESTIGATOR) - University of Pittsburgh
Contact Information
Study Contact:
Julie Research Coordinator
412-509-8787
PEACHY@upmc.edu
Lauren M Bylsma, PhD
412-624-8363
BylsmaL@pitt.edu
University of Pittsburgh
Judith K Morgan, PhD
412-383-5454
jkm46@pitt.edu
University of Pittsburgh
Interventions
  • Behavioral: Parent Coaching — Three sessions of parent coaching of child positive affect will be administered based on modules from PCIT-ED.
  • Behavioral: Active Control — General parent support and psychoeducation based on components of standard PCIT.
Study Locations (1 sites)
University of Pittsburgh, Pittsburgh, Pennsylvania 15213 United States
Eligibility Criteria
Inclusion Criteria for Mothers: * Birth mother (biologically female, any gender) * Providing regular care for participating child (i.e., at least 50% of time) * Elevated, clinically significant levels of depression (16 or higher on CES-D) * Aged 18+ Exclusion Criteria for Mothers: * Lifetime history of a bipolar disorder * Lifetime history of a psychotic disorder Inclusion Criteria for Participating Child: -Aged 4-6 years Exclusion Criteria for Participating Child: * T-score greater than 63 on the internalizing or externalizing composites of the CBCL * Lifetime history of a psychiatric illness * Lifetime history of neurodevelopmental disorder * Lifetime history of neurological disorder
Conditions Asthma
Phase PHASE3
Enrollment 192
Locations 6 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Despite optimal initial emergency department (ED) therapy, 50% of children with severe acute asthma have ongoing moderate-severe respiratory distress. Guidelines recommend intravenous magnesium (IVMg) for them, yet evidence for IVMg efficacy is scant and disparate. While early small Randomized Controlled Trials (RCTs) suggested hospitalization benefit, recent large observational studies found no association between IVMg and improved outcomes. IVMg therapy is resource-intensive, can cause hypotension and demands close monitoring. Previous RCTs only assessed early Mg effect at 1-2 hours, overlooked the peak effect of key co-interventions such as corticosteroids and did not use validated scores. IVMg use is variable and often delayed until ≥4 hours after ED therapy is started and after the hospitalization decision has been made. Thus, in observational studies children given IVMg are 6-10 times more likely to be hospitalized; these studies have major confounding and the true IVMg treatment effect is thus unknown. To conclusively determine if IVMg alters the exacerbation course, it must be given early, and the primary outcome measure should be the severity of respiratory distress measured at the peak effect of key co-interventions to focus on a clinically meaningful and objective effect. The Pediatric Respiratory Assessment Measure (PRAM)-a valid, discriminative, reproducible and responsive-to-change instrument-is thus the ideal primary outcome measure. Hospitalization outcome has major confounding by indication and MD perceptions. Primary Aim: In children with acute asthma remaining in moderate-severe distress after 1 hour of initial ED therapy, is early IVMg therapy associated with a significantly greater improvement in respiratory distress, measured by PRAM, at 2 hours after starting the intervention, compared to placebo? Hypothesis: IVMg will yield significantly greater PRAM improvement of ≥1.0 point than placebo. Expected Outcomes: This trial will clarify if there is an incremental benefit of IVMg in decreasing respiratory distress in pediatric refractory acute asthma. A positive result will establish a proven standard of care for this indication, with a need for Knowledge Translation (KT) to implement routine early IVMg therapy. A negative result will lead to de-implementation of IVMg which may also lead to cost savings.

Design

Study type: Interventional Phases: Phase3 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Quadruple

Interventions / Regimen

  • Drug: magnesium sulfate — After initial therapy with the systemic CSs routinely used for acute asthma management at a given site, 3 treatments with inhaled salbutamol and ipratropium, eligible patients with PRAM ≥5 will, under the care of the research nurse, receive a 30-minute IV infusion of 75 mg/kg of Mg sulfate(maximum 2.0 g) \[experimental group\]
  • Drug: Normal Saline — After initial therapy with the systemic CSs routinely used for acute asthma management at a given site, 3 treatments with inhaled salbutamol and ipratropium, eligible patients with PRAM ≥5 will, under the care of the research nurse, receive a 30-minute IV infusion of 0.9% saline \[control group\].

Primary Outcomes

  • Pediatric Respiratory Assessment Measure (PRAM) score: This score ranges from 0-12. A score from 0-3 is mild, 4-7 moderate and 8-12 severe. A low score is a better outcome and a high score is a worse outcome. (The primary outcome measure will be the PRAM score at 120 minutes post start of experimental therapy.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE3
Status: Recruiting
Start Date: 2025-10-08
Completion: 2027-10
Eligibility
Age: 2 Years and older
Sex: ALL
Volunteers: false
Enrollment: 192 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Suzanne Schuh
Collaborators: Alberta Children's Hospital, McMaster Children's Hospital, Stollery Children's Hospital, Children's Hospital of Eastern Ontario, St. Justine's Hospital, The Hospital for Sick Children
Principal Investigators:
  • Suzanne Schuh, MD (PRINCIPAL_INVESTIGATOR) - The Hospital for Sick Children
Contact Information
Study Contact:
Sunita O'Shea
416-813-7654
sunita.oshea@sickkids.ca
Yaron Finkelstein, MD
416-813-7654
yaron.finkelstein@sickkids.ca
Mohamed Eltorki, MD
mmeltork@ucalgary.ca
Alberta Children's Hospital
Interventions
  • Drug: magnesium sulfate — After initial therapy with the systemic CSs routinely used for acute asthma management at a given site, 3 treatments with inhaled salbutamol and ipratropium, eligible patients with PRAM ≥5 will, under the care of the research nurse, receive a 30-minute IV infusion of 75 mg/kg of Mg sulfate(maximum 2.0 g) \[experimental group\]
  • Drug: Normal Saline — After initial therapy with the systemic CSs routinely used for acute asthma management at a given site, 3 treatments with inhaled salbutamol and ipratropium, eligible patients with PRAM ≥5 will, under the care of the research nurse, receive a 30-minute IV infusion of 0.9% saline \[control group\].
Study Locations (6 sites)
Alberta Children's Hospital, Calgary, Alberta T3B 6A8 Canada
Stollery Children's Hospital, Edmonton, Ontario T6G 2B7 Canada
McMaster Children's Hospital, Hamilton, Ontario L8S 4L8 Canada
Children's Hospital of Eastern Ontario, Ottawa, Ontario K1H 8L1 Canada
The Hospital for Sick Children, Toronto, Ontario M5G 1X8 Canada
CHU-Sainte Justine Hospital, Montreal, Quebec H3T 1C5 Canada
Eligibility Criteria
Inclusion criteria: 1. Age 2.00-17.99 years (prior to 18th birthday), 2. Diagnosis of asthma, defined as an asthma or probable asthma diagnosis/asthma-like phenotype made by a physician (this includes ED physician) in a patient who in the opinion of the treating ED physician requires therapy for acute asthma in the ED (GINA asthma guidelines, 2024). 3. Moderate-severe asthma after initial therapy with 3 treatments of inhaled salbutamol and ipratropium, defined as an eligibility PRAM ≥5, indicating a strong association with hospitalization. Exclusion criteria: 1. Receipt of IVMg within 24 hours prior to ED arrival. 2. Need for airway support on arrival. (Airway support on arrival meeting exclusion criteria will include immediate need for high flow nasal cannula therapy, non-invasive CPAP/bi-PAP ventilation or invasive ventilation with endotracheal intubation, as decided by the attending Emergency Department (ED) physician. Supplemental oxygen therapy will not represent an exclusion criterion.) 3. Known renal, chronic pulmonary, neurologic, cardiac or systemic disease: these may influence outcomes after Mg. 4. Known hypersensitivity to Mg sulfate. 5. Previous enrollment. 6. Poor mastery of English and/or French language precluding informed consent understanding. 7. No phone/email; unavailable for follow-up
Conditions Anxiety, Depression
Phase NA
Enrollment 100
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this clinical trial is to learn if cognitive analytic therapy-guided self-help (CAT-GSH) is comparable to cognitive behavioural therapy-guided self-help (CBT-GSH) in terms of whether it is effective and acceptable for people with anxiety or low mood, who are returning to NHS Talking Therapy services for further treatment. The main questions it aims to answer are: * Does CAT-GSH work well and feel acceptable for people coming back to the Talking Therapies service, compared to CBT-GSH, when taking their characteristics (like age) into account * Does CAT-GSH work well and feel acceptable for people coming back to the Talking Therapies service, compared to those using CBT-GSH for the first time, when taking their characteristics (like age) into account? Participants will: * Choose their preferred treatment * Complete 6 sessions of either CAT-GSH or CBT-GSH * Sessions will be weekly or bi-weekly * Complete routine outcome measures before, during and at the end of therapy

Design

Study type: Interventional Phases: Allocation: Non Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Behavioral: Cognitive analytic therapy guided self-help (CAT-GSH) — Six session CAT-GSH treatment
  • Behavioral: Cognitive behavioural therapy guided self-help (CBT-GSH) — Six session CBT-GSH treatment

Primary Outcomes

  • Composite score (Generalised Anxiety Disorder-7 (GAD-7), Patient health Questionaire-9 (PHQ-9) and Work and Social Adjustment Scale (WSAS)) (From enrolment to the end of treatment after 6 sessions, weekly or bi-weekly. 6-12 weeks.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-07-30
Completion: 2025-12
Eligibility
Age: 16 Years and older
Sex: ALL
Volunteers: false
Enrollment: 100 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Sheffield
Collaborators: Catalyse CAT Limited, Tameside and Glossop Talking Therapies service, Leeds Mental Wellbeing service
Principal Investigators:
  • Andrew J Laphan (PRINCIPAL_INVESTIGATOR) - University of Sheffield
Contact Information
Study Contact:
Andrew J Laphan
01142226650
alaphan1@sheffield.ac.uk
Amrit Sinha
01142226650
a.sinha@sheffield.ac.uk
Jessica Lancashire
+44161 716 4242
jessica.lancashire@nhs.net
Tameside and Glossop NHS Talking Therapies Service
Interventions
  • Behavioral: Cognitive analytic therapy guided self-help (CAT-GSH) — Six session CAT-GSH treatment
  • Behavioral: Cognitive behavioural therapy guided self-help (CBT-GSH) — Six session CBT-GSH treatment
Study Locations (2 sites)
Tameside and Glossop NHS Talking Therapies Service, Ashton-under-Lyne, OL6 7SR United Kingdom
Leeds Mental Wellbeing Service, Leeds, LS9 7TA United Kingdom
Eligibility Criteria
Inclusion Criteria: * Previously received CBT-GSH at same participating NHS Talking Therapies service * Presenting with anxiety or depression * Deemed suitable for step 2 low-intensity therapy, through assessment by a qualified PWP Exclusion Criteria: * Previously received high-intensity therapy since receiving CBT-GSH * The previous treatment episode was in another NHS Talking Therapies service. * Not fluent in English Individuals who are not fluent in English will be excluded from the study due to not having translated CAT-GSH workbooks available and limited funding to translate any workbooks.
Conditions Fibromyalgia, Transcranial Magnetic Stim...
Phase NA
Enrollment 30
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Research on repetitive transcranial magnetic stimulation therapy in fibromyalgia syndrome (FMS) is increasing rapidly. High-frequency rTMS administration to FMS patients is reported to restore intracortical facilitation and provide successful pain relief. This finding supports restoration of cortical stimulation as one of the possible mechanisms of action for rTMS. One treatment protocol is intermittent theta burst stimulation (iTBS, a variant of excitatory rTMS). Although there are many treatment protocols, there are few widely accepted treatment schemes in the literature. In fibromyalgia syndrome, there is no study in the literature. It was planned to include at least 30 patients aged 18-65 years who were admitted to İzmir Katip Çelebi University Atatürk Training and Research Hospital Physical Medicine and Rehabilitation Outpatient Clinic or hospitalized in the ward and diagnosed with fibromyalgia syndrome according to the 2016 criteria. This study has a prospective, parallel group, randomized, sham-controlled study design. A total of 30 fibromyalgia patients will be randomized into 2 groups and will receive a total of 10 sessions of transcranial magnetic stimulation to the primary motor cortex with intermittent theta bust stimulation technique or sham application. Patients will continue their current fibromyalgia treatment.Numeric Rating Scale-pain intensity (NRS-pain), revised Fibromyalgia Impact Questionnaire (FIQR), Pain Catastrophizing Scale (PCS), Hospital Depression Anxiety Scale (HADS) will be used in the evaluation of the patients.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Double

Interventions / Regimen

  • Device: Intermittent theta-burst stimulation — Neuro-MS/D (Neurosoft) rTMS device will be used for stimulation with an angulated figure-of-eight coil. Neuronavigation system will be used to determine the application site. Before each session, active motor threshold (aMT) will be determined by obtaining a motor evoked potential with an amplitude of \>200μV in the EMG recording of the first dorsal interosseous muscle (FDI), which is slightly contracted (10-20% of maximum contraction) in at least five out of 10 stimuli delivered to the primary motor cortex. The handle will be held at a 45° angle to the sagittal plane, pointing backwards and laterally to create posterior-anterior current flow in the brain. The stimulation parameters are as follows: Parameters: Stimulation type:Burst Stimulus amplitude (% MT): 80 Burst frequency in sequence (Hz):5 Pulse frequency within burst (Hz):50 Number of bursts in the sequence: 10 Number of series:20 Interval between sequences: 8 sec Total time: 3min 47sec Total number of pulses: 600
  • Device: Sham Intermittent theta-burst stimulation — In the sham application, the probe of the transcranial magnetic stimulation device will be placed in the vertical position and held perpendicular to the vertex and applied at an ineffective dose so that the patient hears the same sound. In order for the device to produce the same sound and warning sounds as the active application, it will be operated at the lowest operating power of 1 power. In the device operating at this power, there is no possibility of any warning due to the upright position of the probe.

Primary Outcomes

  • Change from baseline in the Numeric Rating Scale ((1) at the beginning of the treatment (T0), (2) at the 1st week (T1), (3) at the 2nd week (T2), (4) four weeks after the end of the treatment (T3).)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-03-13
Completion: 2027-04-01
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 30 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Izmir Katip Celebi University
Contact Information
Study Contact:
Ayhan ASKIN, Professor
902322444444
ayhan.askin@ikc.edu.tr
Ezgi Ayan, MD
902322444444
ezgiugurlu45@icloud.com
Ayhan Aşkın, Professor
902322444444
ayhan.askin@ikc.edu.tr
Izmir Katip Çelebi University Atatürk Training and Research Hospital
Interventions
  • Device: Intermittent theta-burst stimulation — Neuro-MS/D (Neurosoft) rTMS device will be used for stimulation with an angulated figure-of-eight coil. Neuronavigation system will be used to determine the application site. Before each session, active motor threshold (aMT) will be determined by obtaining a motor evoked potential with an amplitude of \>200μV in the EMG recording of the first dorsal interosseous muscle (FDI), which is slightly contracted (10-20% of maximum contraction) in at least five out of 10 stimuli delivered to the primary motor cortex. The handle will be held at a 45° angle to the sagittal plane, pointing backwards and laterally to create posterior-anterior current flow in the brain. The stimulation parameters are as follows: Parameters: Stimulation type:Burst Stimulus amplitude (% MT): 80 Burst frequency in sequence (Hz):5 Pulse frequency within burst (Hz):50 Number of bursts in the sequence: 10 Number of series:20 Interval between sequences: 8 sec Total time: 3min 47sec Total number of pulses: 600
  • Device: Sham Intermittent theta-burst stimulation — In the sham application, the probe of the transcranial magnetic stimulation device will be placed in the vertical position and held perpendicular to the vertex and applied at an ineffective dose so that the patient hears the same sound. In order for the device to produce the same sound and warning sounds as the active application, it will be operated at the lowest operating power of 1 power. In the device operating at this power, there is no possibility of any warning due to the upright position of the probe.
Study Locations (1 sites)
Izmir Katip Çelebi University Atatürk Training and Research Hospital, Izmir, Karabaglar 35290 Turkey (Türkiye)
Eligibility Criteria
Inclusion Criteria: * Being between the ages of 18-65 * Being diagnosed with fibromyalgia syndrome (according to 2016 criteria) * Average pain intensity of NRS ≥ 4/10 * Fibromyalgia treatment was stable for the last 3 months and no treatment change was planned during the study Exclusion Criteria: * Having a clinical condition that would constitute a contraindication for TMS (metallic implant, cardiac pacing, pregnancy, epilepsy, head trauma, history of cranial operation...) * Presence of malignancy * Systemic rheumatologic diseases * Major orthopedic problems limiting activities of daily living (gait disturbance or fracture sequelae limiting joint mobility, prostheses, nerve-tendon injuries) * Serious neurological diseases (increased intracranial pressure, presence of space-occupying lesions in the brain, history of epilepsy, presence of cerebral aneurysm, Parkinson's disease, Huntington's chorea, multiple sclerosis, history of previous head trauma causing loss of consciousness) * Alcohol or drug addiction * History of major depression/personality disorder or psychosis * Having received TMS treatment before * Taking benzodiazepine, gabapentin/pregabalin or anticonvulsant medications that have the potential to interfere with intermittent theta burst stimulation treatment or have taken them within the last 4 weeks * Pregnant or planning pregnancy or breastfeeding